|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> FSGTC treatment significantly relieved the degeneration of cartilage and reduced the contents of tumor necrosis factor-α (TNF-α) and IL-6 in the serum in papain-induced OA rats.
|
30174601 |
2018 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> The results of ELISA (IL-1β and tumor necrosis factor-α), the histological evaluation (Mankin and OARSI score), western blotting [COL2A1, matrix metalloproteinase (MMP)-3, MMP-13, IL-1β, and nuclear factor-kappaB (NF-κB) p65], and immunohistochemistry (COL2A1, MMP-3, and MMP-13) indicated that oral CAR attenuated the development of T2DM-induced OA and suppressed the inflammatory response.
|
29928231 |
2018 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>In vitro</i>, geniposide attenuated the expression of inflammatory cytokines including interleukin-1 (IL-1), tumor necrosis factor (TNF-<i>α</i>), and nitric oxide (NO) production as well as matrix metalloproteinase- (MMP-) 13 in chondrocytes isolated from surgically induced rabbit osteoarthritis model.
|
29682561 |
2018 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
3D cartilage micromasses were treated with tumour necrosis factor-α (TNF-α) (OA-inducer) and/or HA for 7 days.
|
29783732 |
2018 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Osteoarthritis (OA) is a degenerative condition that involves the production of inflammatory cytokines (e.g., interleukin-1β (IL-1β), tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6)) that stimulate degradative enzymes, matrix metalloproteinases (MMPs) and aggrecanases (ADAMTS) resulting in articular cartilage breakdown.
|
31434236 |
2019 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
TNF-a stimulation induced IL-6 secretion by RA SFB (3-fold) and OA SFB (4-fold), as well as MMP-1 secretion (RA, 85-fold; OA, 29-fold), with significant differences between RA and OA.
|
12913922 |
2003 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor-α (TNF-α), a pro-inflammatory cytokine with a critical role in osteoarthritis (OA), was primarily produced by monocytes/macrophages and plays a crucial role in the inflammatory response.
|
22711527 |
2012 |
|
Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Tumour necrosis factor alpha (TNF alpha) was produced spontaneously at high levels by both RA and OA synovial cells.
|
2505790 |
1989 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor α (TNFα) has been identified as a crucial effector modulating OA pathogenesis.
|
25824140 |
2015 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor receptor-associated factor 1 (TRAF1), connective tissue growth factor (CTGF), and chemokine (C-X3-C motif) ligand 1(CX3CL1) genes were hypomethylated in chondrocytes of OA and RA patients, which verified by bisulfite sequencing analysis.
|
28470428 |
2017 |
|
Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TNF-α and IL-1β mRNA levels in CD14-positive cells from the SYN of OA patients was significantly higher than that in CD14-negative cells, while NGF expression did not differ markedly between the two cell fractions.
|
28677145 |
2017 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor (<i>TNF</i>) is an important proinflammatory cytokine involved in bone remodeling and plays essential roles in osteoarthritis and chronic inflammatory bone diseases, including HV.
|
31063409 |
2019 |
|
Degenerative polyarthritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
TNFA gene polymorphic individuals (subjects harboring allele A) are more affected by OA (χ<sup>2</sup> = 8.7, p = 0.003), once they have major radiological lesion both in hip (Fisher-Freeman-Halton Test = 3.9, p = 0.04) and knee (Fisher-Freeman-Halton Test = 4.0, p = 0.04) as well as worse functional status assessed by the Lequesne questionnaire (Mann-Whitney, p = 0.04).
|
31238971 |
2019 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A benzamide-linked small molecule HS-Cf inhibits TNF-α-induced interferon regulatory factor-1 in porcine chondrocytes: a potential disease-modifying drug for osteoarthritis therapeutics.
|
21858617 |
2011 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abnormal loss of components of the extracellular matrix (ECM) including type II collagen and aggrecan caused by proinflammatory cytokines such as tumor necrosis factor-α (TNF-α) is an important pathophysiological characteristic of osteoarthritis (OA).
|
31075239 |
2019 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Abnormal reduction of extracellular matrix (ECM), including type II collagen and aggrecan, caused by tumor necrosis factor-α (TNF-α) is an important pathological feature of osteoarthritis (OA).
|
30096598 |
2018 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Addition of the proinflammatory cytokines tumour necrosis factor (TNF)α, interleukin (IL)-6 and IL-1β, which were increased in RA and PsA SF compared to osteoarthritis (OA) SF, consistently abrogated PD-1-mediated suppression in HC CD4<sup>+</sup> T cell cultures.
|
28245522 |
2017 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, we verified that PDX ameliorated cartilage degradation in monosodium iodoacetate (MIA)-induced OA rats through histological evaluation and ELISA of TNF-α in the serum and intra-articular lavage fluid.
|
31837574 |
2020 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adherent monocytes without any stimulation (Mo(-)) or stimulated with IFN-γ and TNF-α (Mo(IFN-γ/TNF-α)) or IL-4 (Mo(IL-4)) were exposed to SF from 6 donors without any known joint disease (SF-Ctrl), 10 OA donors (SF-OA), and 10 RA donors (SF-RA).
|
26521731 |
2015 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
LHGDN |
Advanced glycation end products increases matrix metalloproteinase-1, -3, and -13, and TNF-alpha in human osteoarthritic chondrocytes.
|
17434489 |
2007 |
|
Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
AID transcription in RA-FLS was augmented by tumour necrosis factor (TNF)-alpha and even by physiological concentration of beta-oestradiol that could not induce AID transcription in osteoarthritis-FLS.
|
20491788 |
2010 |
|
Degenerative polyarthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
All therapies significantly reduced IL-6 and TNF-α protein expression (p < 0.05) compared with the OA group.
|
27726040 |
2017 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a potential treatment for osteoarthritis (OA), we have developed injectable and hydrolytically degradable heparin-based biomaterials with tunable sulfation for the intra-articular delivery of tumor necrosis factor-alpha stimulated gene-6 (TSG-6), a protein known to inhibit plasmin which may degrade extracellular matrix within OA joints.
|
29564448 |
2018 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
As expected, our findings suggest that the anti-inflammatory effects of Guilu Erxian Liquid (GE-L), following marked decrease on both IL-1β and TNF-α during the early course of post-traumatic osteoarthrosis (OA), may be of potential value in the treatment of osteoarthritis.
|
30340603 |
2018 |
|
Degenerative polyarthritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Catalpol also inhibited the nuclear factor kappa B (NF-kappaB) pathway, reduced the production of inflammatory cytokines (IL-6, tumor necrosis factor-alpha) in IL-1ß-treated chondrocytes, and partially reversed cartilage degeneration in the knee joint in animal model of osteoarthritis.
|
31484919 |
2019 |